PMID- 37625665
OWN - NLM
STAT- MEDLINE
DCOM- 20231128
LR  - 20240205
IS  - 1535-7732 (Electronic)
IS  - 1051-0443 (Linking)
VI  - 34
IP  - 12
DP  - 2023 Dec
TI  - Comparison of the Safety of Transjugular and Percutaneous Liver Biopsies.
PG  - 2120-2127.e2
LID - S1051-0443(23)00610-3 [pii]
LID - 10.1016/j.jvir.2023.08.023 [doi]
AB  - PURPOSE: To compare adverse events (AEs) between the transjugular liver biopsy 
      (TJLB) and percutaneous liver biopsy (PLB) approaches. MATERIALS AND METHODS: A 
      total of 1,300 patients who underwent liver biopsy between July 1, 2014 and 
      January 31, 2018, were examined, and bivariate and multivariate analyses were 
      used to determine predictors of the biopsy method used and AEs. To reduce bias in 
      the comparison of the AE rates between patients who had TJLB or PLB, propensity 
      score matching was used to control for baseline disease severity. RESULTS: PLB 
      and TJLB were performed in 601 and 699 patients, respectively. The mean Charlson 
      Comorbidity Index score was 3 (+/-2), and antiplatelet or anticoagulation therapy 
      at the time of biopsy was used in <10% of patients. Patients with suspected 
      cirrhosis or portal hypertension (odds ratio [OR], 9.9), an international 
      normalized ratio of >1.5 (OR, 5.9), or a platelet count of <100 x 10(3)/mL (OR, 
      3.9) were more likely to undergo TJLB. After propensity matching, which 
      identified a population of patients with a mean international normalized ratio of 
      <1.5 and platelet count of >150 x 10(3)/mL, the only difference in the AE rate 
      was for pain, which was present in 8% and 10% of patients after TJLB and PLB, 
      respectively (P < .001). Bleeding requiring transfusion occurred in 2 patients 
      who underwent TJLB and 1 patient who underwent PLB. There was 1 case of death 
      occurring after TJLB. CONCLUSIONS: Severe/life-threatening AEs occurring after 
      liver biopsy were uncommon, and the 2 liver biopsy approaches appeared to have 
      similar safety profiles for low-risk patients. After matching for underlying 
      disease severity, pain was the AE that was more likely to occur in patients who 
      underwent PLB.
CI  - Copyright (c) 2023 SIR. Published by Elsevier Inc. All rights reserved.
FAU - Sasso, Roula
AU  - Sasso R
AD  - Division of Gastroenterology and Hepatology, Medical University of South 
      Carolina, Charleston, South Carolina.
FAU - Khalifa, Ali
AU  - Khalifa A
AD  - Division of Gastroenterology and Hepatology, Medical University of South 
      Carolina, Charleston, South Carolina.
FAU - Guimaraes, Marcelo
AU  - Guimaraes M
AD  - Department of Radiology, Medical University of South Carolina, Charleston, South 
      Carolina.
FAU - Rockey, Don C
AU  - Rockey DC
AD  - Division of Gastroenterology and Hepatology, Medical University of South 
      Carolina, Charleston, South Carolina; Digestive Disease Research Center, Medical 
      University of South Carolina, Charleston, South Carolina. Electronic address: 
      rockey@musc.edu.
LA  - eng
GR  - P20 GM130457/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20230823
PL  - United States
TA  - J Vasc Interv Radiol
JT  - Journal of vascular and interventional radiology : JVIR
JID - 9203369
SB  - IM
MH  - Humans
MH  - Jugular Veins/pathology
MH  - Liver/pathology
MH  - *Liver Diseases/pathology
MH  - Biopsy/adverse effects/methods
MH  - *Hypertension, Portal/etiology
MH  - Pain/etiology
EDAT- 2023/08/26 05:41
MHDA- 2023/11/28 06:42
CRDT- 2023/08/25 19:28
PHST- 2022/06/09 00:00 [received]
PHST- 2023/06/16 00:00 [revised]
PHST- 2023/08/18 00:00 [accepted]
PHST- 2023/11/28 06:42 [medline]
PHST- 2023/08/26 05:41 [pubmed]
PHST- 2023/08/25 19:28 [entrez]
AID - S1051-0443(23)00610-3 [pii]
AID - 10.1016/j.jvir.2023.08.023 [doi]
PST - ppublish
SO  - J Vasc Interv Radiol. 2023 Dec;34(12):2120-2127.e2. doi: 
      10.1016/j.jvir.2023.08.023. Epub 2023 Aug 23.